GC
ARKG icon

Gilfoyle & Co’s ARK Genomic Revolution ETF ARKG Stock Holding History

Gilfoyle & Co’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-200
Closed -$5.6K – 11
2023
Q3 		$5.6K Buy
+200
New +$6.54K 14.36% 3

Other funds holding ARKG

MMEA
Main Management ETF Advisors San Francisco, California $3.3B AUM 33.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Gilfoyle & Co's ARKG Position: Q4 2023 in Review

Gilfoyle & Co sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2023, closing a stake of 200 shares — an estimated $5.6K sold.

Gilfoyle & Co first reported a position in ARKG in Q3 2023 and held it in 1 quarter. The position peaked at $5.6K in Q3 2023. 300 funds tracked by Wall St. Rank hold ARKG as of Q4 2023.

  • Gilfoyle & Co reported no remaining ARK Genomic Revolution ETF position as of Q4 2023 after selling out during the quarter.
  • Gilfoyle & Co sold 200 ARK Genomic Revolution ETF shares in Q4 2023, an estimated $5.6K.
  • Gilfoyle & Co first reported a position in ARK Genomic Revolution ETF in Q3 2023 and held it in 1 quarter.
  • Gilfoyle & Co's ARK Genomic Revolution ETF position peaked at $5.6K in Q3 2023.
  • 300 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2023.

Based on Gilfoyle & Co's 13F filing for Q4 2023, filed 23 Jan 2024.